Status | Study |
Not yet recruiting |
Study Name: Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Condition: Blastic Plasmacytoid Dendritic Cell Neoplasm Hepatosplenic T-Cell Lymphoma Date: 2017-03-01 Interventions: Other: Laboratory Biomarker Analysis |
Recruiting |
Study Name: Risk Stratification of Nodal PTCL Condition: Peripheral T-Cell Lymphoma, Not Otherwise Specified Angioimmunoblastic Date: 2017-01-31 |
Recruiting |
Study Name: A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma Condition: Lymphoma Date: 2017-01-16 Interventions: Drug: plitidepsin Other Name: APLD Aplidine |
Recruiting |
Study Name: VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma Condition: Previously Treated Myelodysplastic Syndrome Recurrent Adult Acute Myeloid Leukemia Date: 2017-01-09 Interventions: Biological: Biological Therapy |
Recruiting |
Study Name: A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Condition: T-cell Lymphoma Angioimmunoblastic T-cell Lymphoma Date: 2015-10-26 Interventions: Drug: Brentuximab vedotin study drug given intravenously to determine efficacy in study diseases |
Recruiting |
Study Name: Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Condition: Anaplastic Large Cell Lymphoma, ALK-Negative Anaplastic Large Cell Lymphoma, ALK-Positive Date: 2015-09-24 Interventions: Drug: Cyclophosphamide Given I |
Recruiting |
Study Name: Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma Condition: Follicular Variant Peripheral T-Cell Lymphoma Recurrent Angioimmunobla Date: 2015-08-10 Interventions: Biological: Anti-ICOS Monoclonal Antibody MEDI-570 |
Recruiting |
Study Name: CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Condition: Peripheral T-Cell Lymphoma Angioimmunoblastic T Cell Lymphoma Date: 2015-07-18 Interventions: Drug: CEOP/IVE/GDP chemotherapy regimen |
Completed |
Study Name: Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Condition: Solid Tumor Glioma Angioimmunoblasti Date: 2014-10-16 Interventions: Drug: AG-221 AG-221 administered orally on every day of 28 day cycles until disease progression or unacc |
Recruiting |
Study Name: Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study Condition: Peripheral T-cell Lymphomas (PTCL) PTCL-NOS Date: 2014-07-21 Interventions: Drug: Ro-CHOEP-21 (PHASE I) |